Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

Journal of Clinical Oncology

Volumn 22, Issue 11, 2004, Pages 2108-2121

  Papandreou, Christos N ^a   Daliani, Danai D ^a   Nix, Darrell ^a   Yang, Hong ^a   Madden, Timothy ^a   Wang, Xuemei ^a   Pien, Christine S ^a   Millikan, Randall E ^a   Tu, Shi Ming ^a   Pagliaro, Lance ^a   Kim, Jeri ^a   Adams, Julian ^a   Elliott, Peter ^a   Esseltine, Dixie ^a   Petrusich, Alexandria ^a   Dieringer, Pauline ^a   Perez, Cherie ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BORTEZOMIB; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CYSTEINE PROTEINASE; MULTIENZYME COMPLEX; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; VOMITING; ADULT; AGED; BLOOD; DRUG ADMINISTRATION; DRUG ANTAGONISM; FEMALE; MIDDLE AGED; NEOPLASM; NONPARAMETRIC TEST; PROSTATE TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CYSTEINE ENDOPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIENZYME COMPLEXES; NEOPLASMS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; STATISTICS, NONPARAMETRIC;

EID: 2942692143     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.106     Document Type: Article

References (36)

1. King RW, Deshaies RJ, Peters J-M, et al: How proteolysis drives the cell cycle. Science 274:1652-1659, 1996
2. Scherr CJ: Cancer cell cycles. Science 284:1672-1677, 1996
3. Read MA, Neish AS, Luscinskas FW, et al: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493-506, 1995
4. Palombella VJ, Rando OJ, Goldberg AL, et al: The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and tha activation of NF-κB. Cell 78:773-785, 1994
5. Zetter BR: Adhesion molecules in tumor metastasis. Semin Cancer Biol 4:219-229, 1993
6. Beg AA, Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782-784, 1996
7. Adams J, Palombella VJ, Sausville EA, et al: Proteasome Inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999
8. An WG, Hwang SG, Trepel JB, et al: Protease inhibitor-induced apoptosis: Accumulation of wt 53, p21 WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14:1275-1283, 2000
9. Kalogeris TJ, Laroux FS, Cockrell A. et al: Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am J Physiol 276:C856-C864, 1999
10. Hideshima T, Chauhan D, Podar K, et al: Novel therapies targeting myeloma cell and its bone marrow microenvironment. Semin Oncol 28:607-612, 2001
11. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
12. Huang S, Pettaway CA, Uehara H, et al: Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-4197, 2001
13. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107:241-246, 2001
14. Keller ET, Chang C, Ershler WB: Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 271:26267-26275, 1996
15. Siegall CB, Schwab G, Nordan RP, et al: Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 50:7786-7788, 1990
16. Garcia-Moreno C, Mendez-Davila C, de La Piedra C, et al: Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts. Prostate 50: 241-246, 2002
17. Giri D, Ozen M, Ittmann M: Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 159:2159-2165, 2001
18. Lou W. Ni Z, Dyer K, et al: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42:239-242, 2000
19. Chung TD, Yu JJ, Spiotto MT, et al: Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 38:199-207, 1999
20. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57:141-146, 1997
21. Twillie DA, Eisenberger MA, Carducci MA, et al: Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542-549, 1995
22. Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor forcis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55:4633-4639, 1995
23. LeBlanc R, Catley LP, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996-5000, 2002
24. Lightcap ES, McCormack TA, Pien CS, et al: Proteasome inhibition measurements: Clinical application. Clin Chem 46:673-683, 2000
25. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for Phase I trial in cancer. Biometrics 46:33-48, 1990
26. O'Quigley J: Estimating the probability of toxicity at the recommended dose following a phase I trial in cancer. Biometrics 48:853-862, 1992
27. Korn EL, Mithune D, Chen T, et al: A comparison of two Phase I trial designs. Stat Med 13:1799-1806, 1994
28. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for Phase I studies. Stat Med 14:1149-1161, 1995
29. O'Quigley J, Shen LZ: Continual reassessment method: A likelihood approach. Biometrics 52:673-684, 1996
30. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
31. Bubley G, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the PSA working group. J Clin Oncol 17:3461-3467, 1999
32. Nix DJ, Pien C, LaButti J, et al: Clinical pharmacology of the proteasome inhibitor PS-341. Proceedings of the 2001 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 7:11, 2001 (abstr 389)
33. Breiman L, Friedman JH, Olshen RA, et al: Classification and regression trees. Belmont, California, Wadsworth International Group, 1984
34. Venables WN and Ripley BD. Modern Applied Statistics with Splus. 3rd edition. New York, Springer, 1999
35. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
36. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002